MaaT Pharma announced plans to formally request the European Medicines Agency reconsider its recent rejection of MaaT013, an innovative treatment designed specifically for aggressive cases of GVHD .
Two high‑impact studies published this week in Nature spotlight difficult-to-treat blood cancers, revealing fresh insight into possible treatment paths. One project found that stifling ADSS2-driven AMP production restored leukemia cells' sensitivity to targeted therapies like BH3 mimetics.
In another breakthrough , scientists silenced the mutant NPM1 gene in AML cells, showing that it reset histone functions and slowed cancer growth.
Meanwhile, hospital staff at Aberdeen briefly handled a hazardous biological agent with potential to transmit serious illness.